RxDoctor Payments Data

Joshua Lee

Orange, CANPI 1063974764

Payments from drug & device makers

$4,794in general payments, 2019–2025

Across 173 payments — averaging $27.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$903
  • Aurinia Pharma U.S., Inc.$901
  • Lilly USA, LLC$726
  • Mallinckrodt Hospital Products Inc.$360
  • Johnson & Johnson$337
  • Novartis$331
  • plus $1K from 12 others

What the payments were for

  • Food & beverage$4,56495%
  • Education$2305%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ActemraTocilizumab11$28,297
Hydroxychloroquine Sulfate58$2,273
Mycophenolate Mofetil11$996
Leflunomide15$967
MethotrexateMethotrexate Sodium41$710
Celecoxib16$385
Cyclobenzaprine Hcl17$123
Duloxetine Hcl11$122
Allopurinol12$96
Prednisone29$90

Paid to pharmacies, not to this prescriber.

Where these figures come from

Is this you, or does something look wrong? →